Takeda Says Rebates, Subsidies Cut $885M IBS Drug Verdict

By Bryan Koenig · August 5, 2026, 7:55 PM EDT

Takeda Pharmaceuticals battled with a class of health plans over whether a Massachusetts federal jury's $885 million antitrust verdict against the drugmaker for conspiring to delay generic competition to anticonstipation drug...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

FWK Holdings LLC et al v. Takeda Pharmaceutical Company Ltd. et al

Case Number

1:21-cv-11057

Court

Massachusetts

Nature of Suit

Anti-Trust

Date Filed

June 25, 2021